ReviewAging and disease2024
Applications of Chitosan and its Derivatives in the Treatment of Osteoarthritis.
Review in Aging and disease, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
7 citing papers in PubMed.
- Proteoglycan-Mimetic Bottle-Brush Polymer Brushes for Osteoarthritis Therapy: Lubrication Enhancement and Multifunctional Disease Modulation.Macromolecular rapid communications · 2026Review
- Review
- Cartilage targeted grape skin-derived extracellular vesicles ameliorate osteoarthritis by attenuating chondrocyte senescence.Journal of nanobiotechnology · 2026Article
- Pharmacological and Biological Efficacy of Chitosan-Based Materials.International journal of molecular sciences · 2025Review
- Progress in the mechanistic understanding of NETs formation in cancer.Medical oncology (Northwood, London, England) · 2025Review
- Recent advances in injectable hydrogels for osteoarthritis treatments.Frontiers in bioengineering and biotechnology · 2025Review
- Crotonylation-related geneFrontiers in nutrition · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Osteoarthritis (OA) is a common joint disease, which is mainly characterized by the degeneration of articular cartilage, inflammation of the synovial membrane of the joint, and changes in the surrounding bone tissue. With the increase of age and weight, the incidence of OA gradually increases, which seriously affects the quality of life of patients. The primary pharmacological treatments for OA include analgesics and non-steroidal anti-inflammatory drugs. However, these medications primarily provide symptomatic relief and are associated with significant side effects. Chitosan, derived from the deacetylation of chitin, has excellent biocompatibility, biodegradability, anti-inflammatory and antioxidant properties, and can promote the repair of articular cartilage. Chitosan can be used as a viscosupplement, drug carrier, cartilage tissue engineering scaffold or other forms. In this review, we systematically summarize the applications of chitosan and its derivatives in the treatment of OA.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.